FDA warns about use of certain glucose monitoring strips

Share this article:

The Food and Drug Administration Friday issued a public health notification regarding certain glucose monitoring strips.

It said that healthcare practitioners should not use GDH-PQQ (glucose dehydrogenase pyrroloquinoline quinine ) test strips on patients receiving therapeutic products containing non-glucose sugars. These sugars can falsely elevate glucose results, which may mask hypoglycemia or prompt excessive insulin administration, leading to a serious injury or death, the FDA said. Patients with serious medical conditions, including kidney failure and rheumatoid arthritis are most likely to use these therapies. Diabetics use glucose monitoring strips to test their blood sugar levels.

Other glucose test strips do not react harmfully with the non-glucose sugars, the FDA noted. The unaffected methods are glucose oxidase, glucose dehydrogenase nicotine adenine dinucleotide (GDH-NAD) or glucose dehydrogenase flavin adenine dinucleotide (GDH-FAD).

For more, click here.

 


Share this article:

More in News

Medicare rates could be adjusted for start and end of hospice care ...

Medicare payments could be adjusted to reflect how hospice services tend to be more intensive at the beginning and end, according to findings recently published by the Centers for Medicare & Medicaid Services Office of Information Products & Data Analytics.

Nursing home resident dies after allegedly being smothered by son

A terminally ill nursing home resident in Ohio has died after his son is alleged to have smothered him, according to police.

Medicare should pay for skilled nursing services without a qualifying hospital stay, experts tell Senators

Medicare should pay for skilled nursing services without ...

The time has come to eliminate hospital stay requirements for beneficiaries to qualify for Medicare coverage of skilled nursing services, experts told a Senate committee Wednesday.